Pluristem Therapeutics, Inc. (NASDAQ:PSTI) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,901,301 shares, a growth of 34.3% from the October 13th total of 1,415,640 shares. Based on an average daily volume of 1,120,080 shares, the short-interest ratio is presently 1.7 days. Currently, 2.2% of the company’s shares are sold short.

Shares of Pluristem Therapeutics (NASDAQ PSTI) opened at $1.41 on Thursday. Pluristem Therapeutics has a 12 month low of $1.04 and a 12 month high of $2.12.

Pluristem Therapeutics (NASDAQ:PSTI) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). equities research analysts anticipate that Pluristem Therapeutics will post -0.34 earnings per share for the current year.

Several research firms have issued reports on PSTI. Maxim Group set a $2.00 price target on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 16th. HC Wainwright reaffirmed a “buy” rating and set a $3.50 price target on shares of Pluristem Therapeutics in a research note on Wednesday, September 6th. ValuEngine cut shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research cut shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $4.38.

Several institutional investors and hedge funds have recently added to or reduced their stakes in PSTI. Heritage Investors Management Corp acquired a new stake in shares of Pluristem Therapeutics in the third quarter worth approximately $113,000. Psagot Investment House Ltd. boosted its position in shares of Pluristem Therapeutics by 1,705.2% in the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 122,347 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Pluristem Therapeutics by 15.0% in the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock worth $402,000 after acquiring an additional 34,742 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Pluristem Therapeutics by 9.1% in the first quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock worth $1,911,000 after acquiring an additional 129,000 shares during the last quarter. 4.08% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Pluristem Therapeutics, Inc. (PSTI) Sees Significant Growth in Short Interest” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/16/pluristem-therapeutics-inc-psti-sees-significant-growth-in-short-interest.html.

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Stock Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related stocks with our FREE daily email newsletter.